AR109683A1 - Anticuerpos contra el factor xi y sus usos - Google Patents
Anticuerpos contra el factor xi y sus usosInfo
- Publication number
- AR109683A1 AR109683A1 ARP170102598A ARP170102598A AR109683A1 AR 109683 A1 AR109683 A1 AR 109683A1 AR P170102598 A ARP170102598 A AR P170102598A AR P170102598 A ARP170102598 A AR P170102598A AR 109683 A1 AR109683 A1 AR 109683A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- sequence
- monoclonal antibody
- antigen
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Reivindicación 1: Un anticuerpo monoclonal o un fragmento de unión a antígeno del mismo, el cual se une específicamente al factor XI humano y/o factor XIa humano caracterizado porque comprende (a) una CDR1 de la cadena liviana que comprende la secuencia KASQSVLYSGDNYLN (SEQ ID Nº 8); (b) una CDR2 de la cadena liviana que comprende la secuencia AASTLES (SEQ ID Nº 9); y (c) una CDR3 de la cadena liviana que comprende la secuencia QQYNGDPWT (SEQ ID Nº 10); (d) una CDR1 de la cadena pesada que comprende la secuencia TSGMGVG (SEQ ID Nº 11); (e) una CDR2 de la cadena pesada que comprende la secuencia HIDWDDDKYYSPSLKS (SEQ ID Nº 12); y (f) una CDR3 de la cadena pesada que comprende la secuencia IRSSVYAHYYGMDY (SEQ ID Nº 13). Reivindicación 10: Un polinucleótido que codifica para un anticuerpo monoclonal o un fragmento de unión a antígeno del mismo caracterizado porque es como se define en cualquiera de las reivindicaciones 1 a 9. Reivindicación 14: Una composición farmacéutica caracterizada porque comprende un anticuerpo monoclonal o un fragmento de unión a antígeno del mismo de acuerdo con cualquiera de las reivindicaciones 1 a 9 o producido de acuerdo con el proceso de la reivindicación 13, el polinucleótido de la reivindicación 10, el vector de la reivindicación 11, y/o la célula huésped de la reivindicación 12, y opcionalmente un excipiente farmacéuticamente aceptable. Reivindicación 19: Un kit caracterizado porque comprende un anticuerpo monoclonal o un fragmento de unión a antígeno del mismo de acuerdo con cualquiera de las reivindicaciones 1 a 9 o producido de acuerdo con el proceso de la reivindicación 13, el polinucleótido de acuerdo con la reivindicación 10, el vector de acuerdo con la reivindicación 11, la célula huésped de acuerdo con la reivindicación 12 o la composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 14 a 16.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016099474 | 2016-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109683A1 true AR109683A1 (es) | 2019-01-09 |
Family
ID=59914459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102598A AR109683A1 (es) | 2016-09-20 | 2017-09-20 | Anticuerpos contra el factor xi y sus usos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10654941B2 (es) |
| EP (1) | EP3515947A1 (es) |
| JP (1) | JP2019537451A (es) |
| KR (1) | KR20190075920A (es) |
| CN (1) | CN110099927A (es) |
| AR (1) | AR109683A1 (es) |
| AU (1) | AU2017329645A1 (es) |
| BR (1) | BR112019005449A2 (es) |
| CA (1) | CA3037087A1 (es) |
| IL (1) | IL265383A (es) |
| MX (1) | MX2019003077A (es) |
| PE (1) | PE20191319A1 (es) |
| RU (1) | RU2758160C2 (es) |
| TW (1) | TW201825523A (es) |
| WO (1) | WO2018054813A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| AU2017286432B2 (en) | 2016-06-14 | 2020-09-24 | Adimab, Llc | Anti-coagulation factor XI antibodies |
| EP3559047A1 (en) | 2016-12-23 | 2019-10-30 | Novartis AG | Factor xi antibodies and methods of use |
| CN117487017A (zh) * | 2020-07-02 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 抗FXI/FXIa抗体、其抗原结合片段及医药用途 |
| CA3188566A1 (en) * | 2020-07-03 | 2022-01-06 | Suzhou Alphamab Co., Ltd. | Coagulation factor xi (fxi) binding protein |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| MXPA05004712A (es) * | 2002-11-07 | 2005-11-23 | Immunogen Inc | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos. |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| AU2014202009A1 (en) * | 2007-11-21 | 2014-05-01 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| US8236316B2 (en) * | 2007-11-21 | 2012-08-07 | Oregon Health & Science University | Anti-factor XI monoclonal antibodies and methods of use thereof |
| EP2373691B1 (en) * | 2008-12-18 | 2019-01-23 | Oregon Health&Science University | Anti-fxi antibodies and methods of use |
| LT2847228T (lt) * | 2012-05-10 | 2018-11-12 | Bayer Pharma Aktiengesellschaft | Antikūnai, galintys jungtis prie koaguliacijos faktoriaus xi ir (arba) jo aktyvuotos formos faktoriaus xia, ir jų panaudojimas |
| JOP20200312A1 (ar) * | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| CA3025896A1 (en) * | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
| CN108884169B (zh) | 2016-01-22 | 2022-03-22 | 默沙东公司 | 抗凝血因子xi抗体 |
-
2017
- 2017-09-18 BR BR112019005449A patent/BR112019005449A2/pt not_active IP Right Cessation
- 2017-09-18 AU AU2017329645A patent/AU2017329645A1/en not_active Abandoned
- 2017-09-18 WO PCT/EP2017/073410 patent/WO2018054813A1/en unknown
- 2017-09-18 JP JP2019536662A patent/JP2019537451A/ja active Pending
- 2017-09-18 US US16/335,133 patent/US10654941B2/en active Active
- 2017-09-18 EP EP17769050.0A patent/EP3515947A1/en active Pending
- 2017-09-18 RU RU2019111862A patent/RU2758160C2/ru active
- 2017-09-18 PE PE2019000666A patent/PE20191319A1/es unknown
- 2017-09-18 CA CA3037087A patent/CA3037087A1/en active Pending
- 2017-09-18 CN CN201780057947.8A patent/CN110099927A/zh active Pending
- 2017-09-18 KR KR1020197011122A patent/KR20190075920A/ko not_active Application Discontinuation
- 2017-09-18 MX MX2019003077A patent/MX2019003077A/es unknown
- 2017-09-19 TW TW106132100A patent/TW201825523A/zh unknown
- 2017-09-20 AR ARP170102598A patent/AR109683A1/es unknown
-
2019
- 2019-03-14 IL IL265383A patent/IL265383A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190225705A1 (en) | 2019-07-25 |
| WO2018054813A1 (en) | 2018-03-29 |
| RU2758160C2 (ru) | 2021-10-26 |
| CN110099927A (zh) | 2019-08-06 |
| CA3037087A1 (en) | 2018-03-29 |
| JP2019537451A (ja) | 2019-12-26 |
| RU2019111862A (ru) | 2020-10-22 |
| BR112019005449A2 (pt) | 2019-10-01 |
| MX2019003077A (es) | 2020-02-05 |
| TW201825523A (zh) | 2018-07-16 |
| KR20190075920A (ko) | 2019-07-01 |
| IL265383A (en) | 2019-05-30 |
| PE20191319A1 (es) | 2019-09-24 |
| EP3515947A1 (en) | 2019-07-31 |
| US10654941B2 (en) | 2020-05-19 |
| AU2017329645A1 (en) | 2019-04-04 |
| AU2017329645A8 (en) | 2019-05-02 |
| RU2019111862A3 (es) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20190398A1 (es) | Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| PE20131209A1 (es) | Anticuerpos anti-fap |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |